Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John A Allen

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Plos One|August 30, 2018
Biophysical validation of serotonin 5-HT2A and 5-HT2C receptor interactionDaniel E Felsing, Noelle C Anastasio, Joanna M Miszkiel, et al.
The American Naturalist|February 25, 2005
A source-sink hypothesis for abyssal biodiversityMichael A Rex, Craig R McClain, Nicholas A Johnson, et al.
Journal of Medicinal Chemistry|May 24, 2024
Discovery of 3-((4-Benzylpyridin-2-yl)amino)benzamides as Potent GPR52 G Protein-Biased AgonistsRyan E Murphy, Pingyuan Wang, Saghir Ali, et al.
Journal of Medicinal Chemistry|November 17, 2020
Discovery of Potent and Brain-Penetrant GPR52 Agonist that Suppresses Psychostimulant BehaviorPingyuan Wang, Daniel E Felsing, Haiying Chen, et al.
Molecular Pharmacology|July 3, 2009
Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine(2B) receptor agonists: implications for drug safety assessmentXi-Ping Huang, Vincent Setola, Prem N Yadav, et al.
Scientific Reports|November 15, 2019
Serotonin 5-HT<sub>2C</sub> Receptor Cys23Ser Single Nucleotide Polymorphism Associates with Receptor Function and Localization In VitroMichelle A Land, Holly L Chapman, Brionna D Davis-Reyes, et al.
Pharmacology Research & Perspectives|August 29, 2018
Small-Molecule Neuromedin U Receptor 2 Agonists Suppress Food Intake and Decrease Visceral Fat in Animal ModelsCatherine M Sampson, James M Kasper, Daniel E Felsing, et al.
Biochemistry|June 27, 2009
Structure-based design, synthesis, and biochemical and pharmacological characterization of novel salvinorin A analogues as active state probes of the kappa-opioid receptorFeng Yan, Ruslan V Bikbulatov, Viorel Mocanu, et al.
Nature Communications|February 16, 2018
Impaired β-arrestin recruitment and reduced desensitization by non-catechol agonists of the D1 dopamine receptorDavid L Gray, John A Allen, Scot Mente, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 25, 2015
Development and validation of a clinical score for predicting risk of adenoma at screening colonoscopyAasma Shaukat, Timothy R Church, Ryan Shanley, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Plos One|August 30, 2018
Biophysical validation of serotonin 5-HT2A and 5-HT2C receptor interactionDaniel E Felsing, Noelle C Anastasio, Joanna M Miszkiel, et al.
The American Naturalist|February 25, 2005
A source-sink hypothesis for abyssal biodiversityMichael A Rex, Craig R McClain, Nicholas A Johnson, et al.
Journal of Medicinal Chemistry|May 24, 2024
Discovery of 3-((4-Benzylpyridin-2-yl)amino)benzamides as Potent GPR52 G Protein-Biased AgonistsRyan E Murphy, Pingyuan Wang, Saghir Ali, et al.
Journal of Medicinal Chemistry|November 17, 2020
Discovery of Potent and Brain-Penetrant GPR52 Agonist that Suppresses Psychostimulant BehaviorPingyuan Wang, Daniel E Felsing, Haiying Chen, et al.
Molecular Pharmacology|July 3, 2009
Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine(2B) receptor agonists: implications for drug safety assessmentXi-Ping Huang, Vincent Setola, Prem N Yadav, et al.
Scientific Reports|November 15, 2019
Serotonin 5-HT<sub>2C</sub> Receptor Cys23Ser Single Nucleotide Polymorphism Associates with Receptor Function and Localization In VitroMichelle A Land, Holly L Chapman, Brionna D Davis-Reyes, et al.
Pharmacology Research & Perspectives|August 29, 2018
Small-Molecule Neuromedin U Receptor 2 Agonists Suppress Food Intake and Decrease Visceral Fat in Animal ModelsCatherine M Sampson, James M Kasper, Daniel E Felsing, et al.
Biochemistry|June 27, 2009
Structure-based design, synthesis, and biochemical and pharmacological characterization of novel salvinorin A analogues as active state probes of the kappa-opioid receptorFeng Yan, Ruslan V Bikbulatov, Viorel Mocanu, et al.
Nature Communications|February 16, 2018
Impaired β-arrestin recruitment and reduced desensitization by non-catechol agonists of the D1 dopamine receptorDavid L Gray, John A Allen, Scot Mente, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 25, 2015
Development and validation of a clinical score for predicting risk of adenoma at screening colonoscopyAasma Shaukat, Timothy R Church, Ryan Shanley, et al.
Pageof 5